BeiGene's PARP Inhibitor Pamiparib Nears Approval in China for BRCA-Mutated Ovarian Cancer

According to the recent update on the official website of the National Medical Products Administration (NMPA), the marketing application for pamiparib, a PARP1/2 inhibitor submitted by BeiGene (Acceptance Number: CXHS2000021), is currently in the “under review” stage and is expected to receive NMPA approval for market launch in the near future. The drug is indicated for the treatment of patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have received two or more prior lines of chemotherapy and harbor known or suspected pathogenic germline BRCA mutations.

It is reported that this will be the fourth PARP inhibitor approved for marketing in China.

According to the NextPharma database from PharmaCube, there are currently five PARP inhibitors marketed globally: olaparib (AstraZeneca/Merck & Co.), niraparib (GSK/Zai Lab), rucaparib (Clovis Oncology), talazoparib (Pfizer), and fluzoparib (Hengrui Medicine). The global market size for PARP inhibitors in 2020 was $3.135 billion, with olaparib accounting for the largest share at 79.8%.

Compiled from: PharmCube